AC Immune’s (ACIU) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock.

ACIU has been the subject of a number of other research reports. Weiss Ratings downgraded shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.50.

AC Immune Price Performance

ACIU opened at $2.36 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The company has a market cap of $240.18 million, a price-to-earnings ratio of -4.37 and a beta of 1.59. The stock has a fifty day simple moving average of $2.36 and a two-hundred day simple moving average of $2.77. AC Immune has a 12-month low of $2.03 and a 12-month high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Wednesday, August 5th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The firm had revenue of $18.67 million for the quarter, compared to analysts’ expectations of $9.59 million. Research analysts predict that AC Immune will post -0.84 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the transaction, the chief executive officer owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On AC Immune

Hedge funds have recently bought and sold shares of the business. EFG International AG bought a new position in AC Immune in the fourth quarter valued at about $41,000. Private Advisor Group LLC purchased a new stake in shares of AC Immune during the 3rd quarter valued at about $48,000. Goldman Sachs Group Inc. increased its position in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of AC Immune in the 3rd quarter worth approximately $63,000. Finally, Sei Investments Co. bought a new position in shares of AC Immune in the 2nd quarter worth approximately $51,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.